Pfizer Takes New Direction With Protalix Pact

December 2009
Chain Drug Review;12/7/2009, Vol. 31 Issue 21, p75
Trade Publication
The article reports on the agreement among Protalix Ltd. and Pfizer Inc. to market expensive medications for the treatment of Gaucher's disease.


Related Articles

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer.  // Bioworld Week;1/10/2011, Vol. 19 Issue 2, p5 

    The article focuses on the 200 million dollars licensing deal with Seattle Genetics Inc. and Pfizer Inc. for the Seagen's antibody-drug conjugate

  • 'Pharmers' hope for first plant drug harvest. Opar, Alisa // Nature Reviews Drug Discovery;Feb2011, Vol. 10 Issue 2, p81 

    The article reports that the U.S. Food and Drug Administration (FDA) is expected to approve the taliglucerase alfa, an enzyme replacement therapy made by the collaborative efforts of Pfizer Inc. and Protalix Ltd. It states that if the taliglucerase alfa would be approved, it would be considered...

  • Pfizer licenses gene for possible AMD therapy.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related...

  • XOMA Gets $30 Million Upfront In Pfizer Technology Deal. Morrison, Trista // BioWorld Today;8/29/2007, Vol. 18 Issue 168, p1 

    The article reports that the shares of antibody company XOMA Ltd. have increased by 18% after it unveiled a license agreement that provides Pfizer Inc. with non-exclusive access to XOMA's patented bacterial cell expression (BCE) technology. XOMA will get a $30 million upfront cash payment in...

  • Finding New Drugs Through Alliances. Koppal, Tanuja // Drug Discovery & Development;Dec2003, Vol. 6 Issue 12, p22 

    Discusses the investment of Pfizer in file enrichment programs to search for drug-like compounds in the U.S. Development of pharmaceutical products through alliances; Negotiation of licensing deals; Value of the portfolio of external collaborations. INSET: Starting out right.

  • Pfizer Taps pSivida Delivery: Up To $165M.  // Bioworld Week;4/9/2007, Vol. 15 Issue 15, p4 

    The article reports on the licensing agreement that takes place between pSivida Ltd. of Perth, Australia, and Pfizer Inc. of New York. The deal, which is set to produce $165 million, will allow pSivida to use sustained-release drug delivery including its Medidur in ophthalmic applications. As...

  • Pfizer and Taisho collaborate on schizophrenia drug.  // PharmaWatch: CNS;Feb2008, Vol. 7 Issue 2, p11 

    The article reports on the definitive agreement signed by Pfizer and Taisho Pharmaceutical for worldwide collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho. Based on the license agreement, Taisho will grant exclusive development...

  • Aspen Holdings, Nestle agreements in respect of the acquisition of certain rights to intellectual property licenses.  // African Business News;4/18/2013, p6 

    The article focuses on the agreements reached by Aspen Holdings with Nestle S.A. in relation to the the acquisition of certain rights to intellectual property licenses, net assets and shares in the infant businesses conducted by Pfizer, concluded in April 2013. Information is given on the infant...

  • NicOx Renews Research Deal with Pfizer in Ophthalmology. Etheridge, James // BioWorld International;1/9/2008, Vol. 13 Issue 2, p1 

    The article reports on the decision of NicOx SA and Pfizer Inc. to renew their collaboration agreement that would give Pfizer the exclusive right to apply the proprietary nitric oxide-donating technology of NicOx to drug discovery research in the field of ophthalmology. NicOx will receive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics